Hegemonic structure of basic, clinical and patented knowledge on Ebola research: A US army reductionist initiative

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Fajardo Ortiz, David ^a   Ortega Sánchez de Tagle, José ^b   Castaño, Victor M ^c  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b Secretaria de Agricultura Ganaderia Desarrollo Rural Pesca y Alimentacion   (Mexico)

^c CENTRO DE FÍSICA APLICADA Y TECNOLOGÍA AVANZADA   (Mexico)

Author keywords

Ebola hemorrhagic fever; Emerging disease; Knowledge translation; National security

Indexed keywords

PROTEIN VP35; PROTEIN VP40; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARMY; ARTICLE; BASIC RESEARCH; CLINICAL RESEARCH; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EPIDEMIC; GENE ONTOLOGY; HEALTH CARE POLICY; HUMAN; MEDICAL RESEARCH; MOLECULAR INTERACTION; NONHUMAN; PROTEIN TARGETING; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS PATHOGENESIS; ATTITUDE TO HEALTH; MEDICAL SUBJECT HEADINGS; PATENT; PHYSIOLOGY; SOLDIER; THEORETICAL MODEL; UNITED STATES;

BIOMEDICAL RESEARCH; EBOLAVIRUS; GENE ONTOLOGY; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MEDICAL SUBJECT HEADINGS; MILITARY PERSONNEL; MODELS, THEORETICAL; PATENTS AS TOPIC; UNITED STATES;

EID: 84929149639     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0496-y     Document Type: Article

References (68)

1. Barry M, Traoré FA, Sako FB, Kpamy DO, Bah EI, Poncin M, et al. Ebola outbreak in Conakry, Guinea: epidemiological, clinical, and outcome features. Med Mal Infect. 2014;44(11-12):491-4. doi:10.1016/j.medmal.2014.09.009. Epub 2014 Oct 23.
2. Shears P, O'Dempsey TJ. Ebola virus disease in Africa: epidemiology and nosocomial transmission. J Hosp Infect. 2015. doi:10.1016/j.jhin.2015.01.002. [Epub ahead of print].
3. Ebola Response Team WHO. Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371(16):1481-95. doi:10.1056/NEJMoa1411100. Epub 2014 Sep 22.
4. Hotez P, Ottesen E, Fenwick A, Molyneux D. The neglected tropical diseases: the ancient afflictions of stigma and poverty and the prospects for their control and elimination. Adv Exp Med Biol. 2006;582:23-33.
5. MacNeil A, Rollin PE. Ebola and Marburg hemorrhagic fevers: neglected tropical diseases? PLoS Negl Trop Dis. 2012;6(6), e1546. doi:10.1371/journal.pntd.0001546. Epub 2012 Jun 26.
6. Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A. 1996;93(8):3602-7.
7. Baron RC, McCormick JB, Zubeir OA. Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bull World Health Organ. 1983;61(6):997-1003.
8. Hoenen T, Feldmann H. Ebolavirus in West Africa, and the use of experimental therapies or vaccines. BMC Biol. 2014;12(1):80 [Epub ahead of print].
9. Gupta R. Rethinking the development of Ebola treatments. Lancet Glob Health. 2014;2(10):e563-4. doi:10.1016/S2214-109X(14)70304-3.
10. Acharya M. Ebola viral disease outbreak-2014: implications and pitfalls. Front Public Health. 2014;2:263. doi:10.3389/fpubh.2014.00263. ECollection 2014.
11. Haynes DM. Still the heart of darkness: the ebola virus and the meta-narrative of disease in the hot zone. J Med Hum. 2002;23(2):133-45.
12. Murdocca C. When Ebola came to Canada: Race and the making of the respectable body. Atlantis. 2003;27(2):24-31.
13. Colhoun D. How xenophobia is driving the Ebola narrative. Columbia J Rev. 2015. Available at http://www.cjr.org/behind_the_news/racialized_ebola_narrative.php?page=all .
14. Preston R. The hot zone (1st ed.). New York: Random House; 2004.
15. Elbe S, Roemer-Mahler A, Long C. Medical countermeasures for national security: A new government role in the pharmaceuticalization of society. Soc Sci Med. 2014. doi:10.1016/j.socscimed.2014.04.035. [Epub ahead of print]
16. Gostin LO, Waxman HA, Foege W. The president's national security agenda: curtailing Ebola, safeguarding the future. JAMA. 2015;313(1):27-8. doi:10.1001/jama.2014.16572.
17. United States National Intelligence Council. National intelligence estimate: the global infectious disease threat and its implications for the United States. Environ Change Secur Proj Rep. 2000;6(1):33-65.
18. Leffel EK, Reed DS. Marburg and Ebola viruses as aerosol threats. Biosecur Bioterror. 2004;2(3):186-91.
19. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, et al. Working Group on Civilian Biodefense. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA. 2002;287(18):2391-405.
20. Letter to the Speaker of the House on emergency appropriations request (and enclosures). President Barack Obama. https://www.whitehouse.gov/the-pressoffice/2014/11/05/letter-president-emergency-appropriations-request-ebola-fiscal-year-2015 .
21. Shibata N, Kajikawa Y, Takeda Y, Sakata I, Matsushima K. Detecting emerging research fronts in regenerative medicine by the citation network analysis of scientific publications. Technol Forecast Soc Change. 2011;78(2):274-82.
22. Murmann JP, Frenken K. Toward a systematic framework for research on dominant designs, technological innovations, and industrial change. Res Policy. 2006;35(7):925-52.
23. Fajardo-Ortiz D, Duran L, Moreno L, Ochoa H, Castaño VM. Liposomes versus metallic nanostructures: differences in the process of knowledge translation in cancer. Int J Nanomedicine. 2014;9:2627-34. doi:10.2147/IJN.S62315.
24. Fajardo-Ortiz D, Duran L, Moreno L, Ochoa H, Castaño VM. Mapping knowledge translation and innovation processes in Cancer Drug Development: the case of liposomal doxorubicin. J Transl Med. 2014;12:227. doi:10.1186/s12967-014-0227-9.
25. Fajardo-Ortiz D, Castaño VM. Patenting Networking and Knowledge Translation in Liposomes for Cancer Therapy. Recent Patents Nanomed. 2014 [Epub ahead of print]. doi:10.2174/1877912305666150121001330
26. Falagas ME, Pitsouni EI, Malietzis GA, Pappas G. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. FASEB J. 2008;22(2):338-42.
27. Newman ME. Power laws, Pareto distributions and Zipf's law. Contemp Phys. 2005;46:323-51.
28. Garfield E. From the science of science to Scientometrics visualizing the history of science with HistCite software. J Informetr. 2009;3:173-9.
29. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc. 2007;2:2366-82.
30. Spinelli L, Gambette P, Chapple CE, Robisson B, Baudot A, Garreta H, et al. Clust&see: a Cytoscape plugin for the identification, visualization and manipulation of network clusters. Biosystems. 2013;113:91-5.
31. Newman ME. Fast algorithm for detecting community structure in networks. Phys Rev E. 2004;69:066133.
32. Doms A, Schroeder M. GoPubMed: exploring PubMed with the Gene Ontology. Nucleic Acids Res. 2005;33:W783-6.
33. Gene Ontology Consortium. The Gene Ontology project in 2008. Nucleic Acids Res. 2008;36:D440-4.
34. Lowe HJ, Barnett GO. Understanding and using the medical subject headings (MeSH) vocabulary to perform literature searches. JAMA. 1994;271:1103-8.
35. Higuchi K. Analysis of free comments in a questionnaire survey: Quantitative analysis by KH Coder. Shakai Chosa. 2012;8:92-6 (In Japanese).
36. Hachiken H, Mastuoka A, Murai A, Kinoshita S, Takada M. Quantitative analyses by text mining of journal articles on medical pharmacy. Japanese J Drug Inform. 2012;13:152-9 (In Japanese).
37. Shineha, Ryuma, Aiko Hibino, and Kazuto Kato. "Analysis of Japanese Newspaper Articles on Genetic Modification". J Sci Commun 2008, 7(2). http://jcom.sissa.it/archive/07/02/Jcom0702(2008)A02/ .
38. Thomson Reuters. Derwent Innovations Index®. Available at: http://sub3.webofknowledge.com .
39. Bray M1, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis. 1999;179 Suppl 1:S248-58.
40. Xu L, Sanchez A, Yang Z, Zaki SR, Nabel EG, Nichol ST, et al. Immunization for Ebola virus infection. Nat Med. 1998;4(1):37-42.
41. Department of Microbiology and Immunology. Thomas W Geisbert profile available at http://microbiology.utmb.edu/faculty/Geisbert.asp .
42. Geisbert TW, Jahrling PB, Hanes MA, Zack PM. Association of Ebola-related Reston virus particles and antigen with tissue lesions of monkeys imported to the United States. J Comp Pathol. 1992;106(2):137-52.
43. Le Guenno B, Formenty P, Wyers M, Gounon P, Walker F, Boesch C. Isolation and partial characterisation of a new strain of Ebola virus. Lancet. 1995;345(8960):1271-4.
44. Timmins J, Scianimanico S, Schoehn G, Weissenhorn W. Vesicular release of ebola virus matrix protein VP40. Virology. 2001;283(1):1-6.
45. Jasenosky LD, Neumann G, Lukashevich I, Kawaoka Y. Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol. 2001;75(11):5205-14.
46. Basler CF1, Wang X, Mühlberger E, Volchkov V, Paragas J, Klenk HD, et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A. 2000;97(22):12289-94.
47. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol. 2003;163(6):2347-70.
48. Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, Pulendran B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol. 2003;170(6):2797-801.
49. Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Mühlberger E, Bray M, et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol. 2003;77(14):7945-56.
50. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debré P, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med. 1999;5(4):423-6.
51. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis. 2002;8(5):503-7.
52. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med. 2000;6(8):886-9.
53. Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006;13(11):1267-77. Epub 2006 Sep 20.
54. Fajardo-Ortiz D, Ochoa H, García L, Castaño V. [Translation of knowledge on cervical cancer: is there a gap between research on causes and research on patient care?]. Cad Saude Publica. 2014;30(2):415-26. doi:10.1590/0102-311X00168512. (In Spanish).
55. Merlin T, Weston A, Tooher R. Extending an evidence hierarchy to include topics other than treatment: revising the Australian 'levels of evidence'. BMC Med Res Methodol. 2009;9:34. doi:10.1186/1471-2288-9-34.
56. Cohen J, Kupferschmidt K. Infectious Diseases. Ebola vaccine trials raise ethical issues Science. 2014;346(6207):289-90. doi:10.1126/science.346.6207.289.
57. Rid A, Emanuel EJ. Ethical considerations of experimental interventions in the Ebola outbreak. Lancet. 2014;384(9957):1896-9. doi: 10.1016/S0140-6736(14)61315-5. Epub 2014 Aug 22.
58. Hantel A, Olopade CO. Drug and vaccine access in the Ebola epidemic: advising caution in compassionate use. Ann Intern Med. 2015;162(2):141-2. doi:10.7326/M14-2002.
59. Edgar EP. USAMRIID: Biodefense Solutions to Protect our Nation. Wellcome letter to the website of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). Available at: http://www.usamriid.army.mil/ .
60. Takada A, Robison C, Goto H, Sanchez A, Murti KG, Whitt MA, et al. A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci U S A. 1997;94(26):14764-9.
61. Simmons G, Wool-Lewis RJ, Baribaud F, Netter RC, Bates P. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol. 2002;76(5):2518-28.
62. Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, Schmaljohn A, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A. 2003;100(26):15889-94.
63. Bente D, Gren J, Strong JE, Feldmann H. Disease modeling for Ebola and Marburg viruses. Dis Model Mech. 2009;2(1-2):12-7. doi:10.1242/dmm.000471.
64. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377(9768):849-62. doi:10.1016/S0140-6736(10)60667-8.
65. Strauss S. Ebola research fueled by bioterrorism threat. CMAJ. 2014;186(16):1206. doi:10.1503/cmaj.109-4910. Epub 2014 Oct 6.
66. Sarewitza D, Pielke RAJ. The neglected heart of science policy: reconciling supply of and demand for science. Environ Sci Policy. 2007;10(1):5-16.
67. Wallace ML, Rafols I. "Research Portfolios in Science Policy: Moving from Financial Returns to Societal Benefits". 2014. Available at SSRN: http://dx.doi.org/10.2139/ssrn.2500396 .
68. Saito R, Smoot ME, Ono K, Ruscheinski J, Wang PL, Lotia S, et al. A travel guide to cytoscape plugins. Nat Methods. 2012;9(11):1069-76.